New drug BL-B16D1 enters human testing for tough cancers
NCT ID NCT06493864
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called BL-B16D1 in 21 adults with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will receive the drug and be closely monitored for side effects and any signs of cancer control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.